OncLive TV

OncLive® TV is an editorial video program featuring one-on-one live and/or virtual interviews with key opinion leaders in the oncology field for their expert insight on breaking news, regulatory updates, practice-changing data presented at medical meetings, and other pivotal topics in a cancer specialty, including breast cancer, lung cancer, genitourinary cancers, gastrointestinal cancers, gynecologic cancers, and hematologic cancers.

Dr. Nallapareddy on the Use of ctDNA Testing in Colorectal Cancer

June 19th 2019

Sujatha Nallapareddy, MD, gastrointestinal medical oncologist at Rocky Mountain Cancer Centers, discusses the use of circulating tumor DNA (ctDNA) testing in patients with colorectal cancer (CRC).

Dr. Einstein on Novel Imaging Tools in Prostate Cancer

June 19th 2019

David J. Einstein, MD, genitourinary medical oncologist, Beth Israel Deaconess Medical Center, discusses novel imaging tools used in prostate cancer.

Dr. Papadimitrakopoulou on Distinguishing Features of the Guardant360 Assay in Lung Cancer

June 19th 2019

Vassiliki A. Papadimitrakopoulou, MD, professor of medicine, Department of Thoracic/Head and Neck Medical Oncology, the University of Texas MD Anderson Cancer Center, discusses distinguishing features of the Guardant360 assay in non–small cell lung cancer (NSCLC).

Dr. Mehta on Rationale for a Phase II Trial of TAS-102/Ramucirumab in Gastric/GEJ Cancer

June 19th 2019

Rutika Mehta, MD, MPH, gastrointestinal medical oncologist, Moffitt Cancer Center, discusses the rationale and design of a phase II study of TAS-102 (trifluridine/tipiracil; Lonsurf) in combination with ramucirumab (Cyramza) in patients with advanced, refractory gastric or gastroesophageal junction (GEJ) adenocarcinoma (NCT03686488).

Dr. McGregor on Guidelines Regarding ADT-Associated Cardiac AEs in Prostate Cancer

June 19th 2019

Pei-Chun McGregor, MD, cardio-oncologist and director of Ambulatory Cardiology at VA Boston Healthcare System, instructor in medicine, Brigham and Women’s Hospital, discusses guidelines regarding androgen deprivation therapy (ADT)-associated cardiac adverse events (AEs) in prostate cancer.

Dr. Hall on the Importance of Genetic Testing in Pancreatic Cancer

June 19th 2019

Michael J. Hall, MD, MS, chair, Department of Clinical Genetics, director, Gastrointestinal Risk Assessment, associate professor, Fox Chase Cancer Center, discusses the importance of genetic testing in pancreatic cancer.

Dr. Fenske Discusses Ongoing Study in Frontline MCL

June 19th 2019

Timothy Fenske, MD, MS, an associate professor at the Medical College of Wisconsin, discusses an ongoing study in the frontline treatment of mantle cell lymphoma.

Dr. Nagawaka Discusses Findings of the RELAY Trial in EGFR+ NSCLC

June 19th 2019

Kazuhiko Nakagawa, MD, PhD, Department of Medical Oncology, Kindai University Faculty of Medicine, Osaka-Sayama, Osaka, Japan, discusses findings of the RELAY trial in EGFR-positive non–small cell lung cancer.

Dr. Gadgeel on Updated KEYNOTE-189 Data in NSCLC

June 18th 2019

Shirish M. Gadgeel, MD, MBBS, professor, University of Michigan Medicine, discusses the updated results of the phase III KEYNOTE-189 trial in metastatic nonsquamous non-small cell lung cancer (NSCLC).

Dr. Jain on Results of Gender Disparities Study in Oncology

June 18th 2019

Shikha Jain, MD, hematologist/oncologist, Rush University Medical Center, discusses the disparities between male and female professionals at medical conferences, specifically the American Society of Clinical Oncology (ASCO) Annual Meeting.

Dr. Fidler on Novel Chemotherapy Strategies in Nonsquamous NSCLC

June 18th 2019

Mary J. Fidler, MD, associate professor, Rush University Medical Center, discusses progression-free survival (PFS) and overall survival (OS) in patients with stage IV, nonsquamous, non–small cell lung cancer patients (NSCLC) treated with first-line pemetrexed and platinum followed by pemetrexed maintenance.

Dr. Davids on the Use of CAR T-Cell Therapy in CLL

June 18th 2019

Matthew S. Davids, MD, MMSc, associate director, Center for Lymphocytic Leukemia, physician, Dana-Farber Cancer Institute, and assistant professor of medicine, Harvard Medical School, discusses the use of CAR T-cell therapy for the treatment of patients with chronic lymphocytic leukemia (CLL).

Dr. Ou on the FDA Approval of Pembrolizumab in SCLC

June 18th 2019

Sai-Hong Ignatius Ou, MD, PhD, Health Science Associate Clinical Professor, University of California, Irvine, Chao Family Comprehensive Cancer Center, University of California Irvine Medical Center, Orange, California, discusses the FDA approval of pembrolizumab (Keytruda) in small cell lung cancer (SCLC).

Dr. Kumthekar Discusses Frontline Therapy for Anaplastic Astrocytoma

June 18th 2019

Priya U. Kumthekar, MD, assistant professor of neurology and medicine, Northwestern University Feinberg School of Medicine, discusses frontline therapy for patients with anaplastic astrocytoma.

Dr. Bekaii-Saab on Tolerability of Encorafenib, Binimetinib, and Cetuximab in BRAF+ CRC

June 17th 2019

Tanios Bekaii-Saab, MD, professor of medicine, Mayo Clinic, discusses the tolerability of encorafenib, binimetinib, and cetuximab in BRAF V600E-mutated metastatic colorectal cancer.

Dr. Tagawa on Next Steps With Sacituzumab Govitecan in Advanced Urothelial Carcinoma

June 17th 2019

Scott T. Tagawa, MD, Richard A. Stratton Associate Professor in Hematology and Oncology, associate professor of clinical medicine & urology at Weill Cornell Medicine, associate attending physician, NewYork-Presbyterian–Weill Cornell Medical Center, discusses next steps with sacituzumab govitecan in advanced urothelial carcinoma.

Dr. Caffo Discusses Enzalutamide/Docetaxel Combination in Frontline mCRPC

June 17th 2019

Orazio Caffo, MD, director of medical oncology at the Santa Chiara Hospital in Trento, Italy, discusses enzalutamide plus docetaxel combination for the frontline treatment of metastatic castration-resistant prostate cancer.

The Clinical Utility of Immunoscore in Stage III CRC

June 14th 2019

Jerome Galon, PhD, research director, French Institute of Health and Medical Research, discusses the prognostic value of Immunoscore in stage III colorectal cancer.

Dr. Wong Discusses Recent Negative Trials in Glioblastoma

June 14th 2019

Eric T. Wong, MD, associate professor of neurology at Harvard Medical School and co-director of the Brain Tumor Center at Beth Israel Deaconess Medical Center, discusses recent negative trials in glioblastoma.

Dr. Lieu on HER2-Directed Therapy in CRC

June 14th 2019

Christopher Lieu, MD, director, GI Medical Oncology Program and deputy associated director for clinical research, at the University of Colorado Cancer Center, discusses HER2-directed therapy for patients with colorectal cancer (CRC).